scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1112926652 |
P356 | DOI | 10.1186/S13058-019-1127-Y |
P932 | PMC publication ID | 6429830 |
P698 | PubMed publication ID | 30898150 |
P50 | author | David Croucher | Q58447784 |
D Neil Watkins | Q88619019 | ||
Sharissa L Latham | Q40325796 | ||
P2093 | author name string | Elgene Lim | |
Walter Kolch | |||
Thomas R Cox | |||
Sean P Kennedy | |||
Neil Portman | |||
Paul Timpson | |||
Darren N Saunders | |||
Max Nobis | |||
Kendelle J Murphy | |||
Robert F Shearer | |||
Amaya Garcia Munoz | |||
Antonia L Cadell | |||
Gabriella R Marriott | |||
Jeremy Z R Han | |||
Yolande E I O'Donnell | |||
James T Williams | |||
Jordan F Hastings | |||
Dushan Miladinovic | |||
P2860 | cites work | An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 |
Mechanism of activation and inhibition of the HER4/ErbB4 kinase | Q24310089 | ||
The protein kinase complement of the human genome | Q24324497 | ||
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Q45945230 | ||
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. | Q48055457 | ||
Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges | Q49887925 | ||
Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers. | Q51646294 | ||
A dimerization motif for transmembrane α–helices | Q54246480 | ||
Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. | Q55261407 | ||
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update | Q57106143 | ||
Nerve Growth Factor Cooperates with p185HER2in Activating Growth of Human Breast Carcinoma Cells | Q62604220 | ||
Multistrip western blotting to increase quantitative data output | Q83684729 | ||
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q88502132 | ||
Cell signaling by receptor tyrosine kinases | Q24598357 | ||
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes | Q24630783 | ||
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily | Q27654013 | ||
Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 | ||
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
Untangling the ErbB signalling network | Q27860884 | ||
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family | Q28073335 | ||
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family | Q28609130 | ||
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation | Q30497820 | ||
Detecting protein-protein interactions with a green fluorescent protein fragment reassembly trap: scope and mechanism. | Q31138784 | ||
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer | Q35112894 | ||
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer | Q35742383 | ||
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 | Q35779325 | ||
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer | Q37633741 | ||
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients | Q38809615 | ||
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial | Q38953228 | ||
Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway | Q39200111 | ||
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors | Q39355055 | ||
Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation | Q39528062 | ||
Pertuzumab and trastuzumab: the rationale way to synergy | Q39701009 | ||
All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. | Q39941394 | ||
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research | Q40445359 | ||
ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 | ||
Specificity within the EGF family/ErbB receptor family signaling network | Q41721612 | ||
HER-2/neu oncogene protein and prognosis in breast cancer | Q41927421 | ||
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | Q42677733 | ||
High-sensitivity measurements of multiple kinase activities in live single cells | Q42735283 | ||
The single transmembrane domains of ErbB receptors self-associate in cell membranes | Q43821697 | ||
Evidence for new homotypic and heterotypic interactions between transmembrane helices of proteins involved in receptor tyrosine kinase and neuropilin signaling | Q44023503 | ||
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Erb-b2 receptor tyrosine kinase 2 | Q415271 |
pertuzumab | Q1998021 | ||
protein heterodimerization activity | Q14762999 | ||
P304 | page(s) | 43 | |
P577 | publication date | 2019-03-21 | |
P1433 | published in | Breast Cancer Research | Q2208481 |
P1476 | title | Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer | |
P478 | volume | 21 |
Q92782594 | An Optimised Protocol Harnessing Laser Capture Microdissection for Transcriptomic Analysis on Matched Primary and Metastatic Colorectal Tumours |
Q96228738 | Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma |
Q100751537 | Attenuation of p53 mutant as an approach for treatment Her2-positive cancer |
Q91694832 | circMAN1A2 could serve as a novel serum biomarker for malignant tumors |
Search more.